Kidney cancer mortality rates decrease across US in past 2 decades
Click Here to Manage Email Alerts
Key takeaways:
- Age-adjusted mortality rates in kidney cancer have decreased in the U.S. over the last 2 decades.
- Better kidney cancer care is needed in non-metro areas to reduce the gap between rural and urban populations.
CHICAGO —Age-adjusted mortality rates in kidney cancer have decreased across all genders, races and ethnicities and in most states in the U.S. over the past 2 decades, according to a poster presentation at ASCO Annual Meeting.
In their study, Nour Abdallah, MD, a postdoctoral research fellow at Cleveland Clinic, and colleagues examined trends in age-adjusted kidney cancer mortality rates by gender, race and ethnicity in the U.S. at national and state levels.
Using national and state-wide kidney cancer mortality data from 1999-2020 from the CDC Wonder database, researchers found 284,224 deaths occurred over the 20-year period, with a decrease in recent years. Men had a lower decrease in age-adjusted mortality rate (ASMR), while maintaining a significantly higher ASMR throughout. National trends based on 2013 National Center for Health Statistics Urban-Rural Classification Scheme for Counties were analyzed to evaluate the difference in metro and non-metro regions.
American Indian patients had the highest mortality rate of 5.7, but white patients had the highest ASMR of 3.9 in 2020 due to a smaller decrease in white compared with nonwhite patients, the findings showed. Non-metro-regions had higher ASMR throughout the study. There was a 15% decline in ASMR in metro regions and only a 4.7% decline in non-metro regions.
The researchers concluded that the lower kidney cancer mortality rate is likely due to earlier detection and improved treatments. However, they noted that the differences in outcomes by gender, race and ethnicity emphasize the need for strategies to better understand the etiology of differences and address disparities.